Genetics of biliary tract cancers and emerging targeted therapies. - Wikidata - awgldk - TriplyDB

Genetics of biliary tract cancers and emerging targeted therapies.

Genetics of biliary tract cancers and emerging targeted therapies.

http://www.wikidata.org/entity/Q37765099

about

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas Gallbladder Cancer in the 21st Century.Cholangiocarcinoma Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.DMBT1 expression in biliary carcinogenesis with correlation of clinicopathological data.A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels.Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy.Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo.Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer Capsaicin treatment attenuates cholangiocarcinoma carcinogenesis Gall bladder carcinoma: Aggressive malignancy with protean loco-regional and distant spread.Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer.Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.Intrahepatic cholangiocarcinoma: expert consensus statement.Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis Biliary tract cancers: SEOM clinical guidelines Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma.Molecular genetics and targeted therapeutics in biliary tract carcinoma.Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer.Cancer detection by ubiquitin carboxyl-terminal esterase L1 methylation in pancreatobiliary fluids.Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer.Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing.Current status of chemotherapy for the treatment of advanced biliary tract cancer.Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer.Current status of immunotherapy for the treatment of biliary tract cancer.A case report of the clear cell variant of gallbladder carcinoma.

P2860

Q24610836-4DF5B65B-5A27-41B2-87F0-32575B29779E Q26784174-20D87E1E-A5D0-4AA1-A4D3-CBE1F218C455 Q27001694-66A15C8F-4120-4AB7-AABC-0583B4F72F1C Q27002547-819D3F23-D611-4EDD-9FFA-D33D7363B500 Q27026833-55A642AF-E558-44BC-954E-F880A8422DE9 Q28109676-42E02181-302B-46FB-86DD-1B6D05F844EC Q30405398-7A98AE4A-C5FC-49CD-AF42-C4AA6684EAA7 Q31157475-3163B14C-650B-4E47-B18D-F7D542638A9A Q33411061-C92E9CF8-ED82-4DA2-A26C-C6BCE66864B1 Q33556032-D918EA8F-D50F-4F50-B877-CDE8125509CB Q33757003-8CEA744F-0881-4079-9866-40837FDAD450 Q33757122-D2704719-6318-4E1F-BA2E-066701302E6D Q33814916-061CFB61-D81E-4E4E-BEB8-BCDD05622284 Q33829684-300B02DA-C69F-4C13-AD39-D9E3F36C0A2B Q33936179-6F66708A-ECA3-419E-9A15-664DB8085990 Q33994406-3E71C98A-4ED8-4E1C-8AFE-8128B3921E1B Q34340578-BF7D2E65-1511-4F0B-965D-AF56221DEBE0 Q35035238-B7F7290A-1CF7-42B0-A633-0B866B27E760 Q35150642-5008C490-E39A-41B2-8198-3968D228CB17 Q35153098-7E5F7728-493A-4ADE-853B-89424DAA5A7F Q35179333-AC9A64DC-B8DF-4C2A-BDCB-4254FC9F6CA0 Q35696749-C91E307C-D936-4DA5-9A3D-416F9DA58C07 Q35820533-82C2967D-474A-4E05-960F-F27083678B2B Q35842729-4E98C1A0-449D-4EDA-B56B-FAEBE11C5603 Q35924971-D7EEEDBD-A9C1-4F05-89D9-14343D9A9D10 Q36224475-2486813B-4280-4E50-B587-5393E0E3DF53 Q36400234-73DEEBDC-81E2-44EC-B210-25782A19AECA Q36414244-049ECBD5-3C5F-46A6-95F6-2F29B2AFAE6A Q36488070-86F73451-4716-4B01-B41F-E612CA1039D8 Q36501683-075BBF9D-535C-4427-B5C7-51539700CC67 Q36609503-5DB6F49B-F13D-4121-AA80-3790A3240FE4 Q36683019-FD0823CF-3FDF-44B6-AF00-B470F4955552 Q36715039-F6BA5F11-2B74-41D2-BE90-9883071E52D7 Q36750601-196B291B-93D0-4809-ABD0-065276C1A55F Q36759538-AF5FAE05-6491-431B-ABA3-7BCBBDE81DF9 Q36870198-1A055332-3911-4C02-A3D4-0601F7BA8520 Q37138732-BC916325-70AF-4718-B512-3EC39225D744 Q37322987-1F320219-78CE-4888-ACD4-DF820185F456 Q37505379-6D9D8C0E-B1DB-4FD8-9EAF-3BA92B25809D Q37653477-EE5F0BAB-CCE7-4B0A-A89F-7ECAB758775D

P2860

Genetics of biliary tract cancers and emerging targeted therapies.

http://www.wikidata.org/entity/Q37765099

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 June 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Genetics of biliary tract cancers and emerging targeted therapies.

@en

Genetics of biliary tract cancers and emerging targeted therapies.

@nl

type

label

Genetics of biliary tract cancers and emerging targeted therapies.

@en

Genetics of biliary tract cancers and emerging targeted therapies.

@nl

prefLabel

Genetics of biliary tract cancers and emerging targeted therapies.

@en

Genetics of biliary tract cancers and emerging targeted therapies.

@nl

P1433

Q37765099-ED288C58-214C-4235-BDE6-0BAF3E05EEC1

P1476

Q37765099-395BAAAD-0FEF-46FE-82E4-E108F66F83FC

P2093

Q37765099-4454915E-95A7-4564-A906-55FCA6FDE7D5

Q37765099-53BA94DE-993D-46B1-8309-AB2AE7B86F5F

Q37765099-C9D3D734-439F-46A7-834C-2B0C01EDF38A

P2860

Q37765099-008E73F1-A881-448C-8DFA-C74408B2F7FB

Q37765099-023695B7-CF87-456F-AC59-B804F107A99E

Q37765099-0496CBD3-F0AF-4546-B5EF-C3C19F0B7DF4

Q37765099-062A0E16-4453-4942-9A5A-9092DB1D5DD2

Q37765099-071E24FC-747C-4BC4-9175-5219A9E23A45

Q37765099-0757C224-5370-479A-BCFF-0E13337E6E5C

Q37765099-12A093DB-3450-4915-B2F5-0DC5770ADF95

Q37765099-12F84DAE-5A42-43AB-A310-729455DF654D

Q37765099-14CF2D3F-6F44-417F-B790-7DD01071425B

Q37765099-1B35C1C6-B098-4360-872F-1F59F85642F3

P304

Q37765099-D4C027F5-9827-4024-81AA-15A7B8477FBA

P31

Q37765099-D59B5219-E564-4B77-8560-D61E4AA82F47

P356

Q37765099-AC115C76-6D19-4FD1-8CB6-6792A80E0B17

P407

Q37765099-AA7C25FA-C1C4-4530-9576-32639714275E

P433

Q37765099-03D79EFD-7E65-4E4C-9703-49BFA95216ED

P478

Q37765099-39898F18-A13C-4858-A949-A27F45FFDF45

P577

Q37765099-E439C99E-6432-4F98-AEA7-734367C5C61A

P698

Q37765099-FED2945B-F6FC-4FEB-B3BC-09A77ED33260

P932

Q37765099-F275EBDE-4A75-4B3F-8FAC-9C1CCAFADF6F

P356

JCO.2009.27.4787

P1433

Journal of Clinical Oncology

P1476

Genetics of biliary tract cancers and emerging targeted therapies.

@en

P2093

Andrew X Zhu

http://www.w3.org/2001/XMLSchema#string

Aram F Hezel

http://www.w3.org/2001/XMLSchema#string

Vikram Deshpande

http://www.w3.org/2001/XMLSchema#string

P2860

Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Genetic alterations during colorectal-tumor development

TGFbeta in Cancer

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

LKB1 modulates lung cancer differentiation and metastasis

Pancreatic cancer.

Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma.

Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.

P304

3531-3540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.27.4787

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20547994

http://www.w3.org/2001/XMLSchema#string

P932

2982782

http://www.w3.org/2001/XMLSchema#string